» Articles » PMID: 37277175

Herd Immunity, Vaccination and Moral Obligation

Overview
Journal J Med Ethics
Specialty Medical Ethics
Date 2023 Jun 5
PMID 37277175
Authors
Affiliations
Soon will be listed here.
Abstract

The public health benefits of herd immunity are often used as the justification for coercive vaccine policies. Yet, 'herd immunity' as a term has multiple referents, which can result in ambiguity, including regarding its role in ethical arguments. The term 'herd immunity' can refer to (1) the herd immunity threshold, at which models predict the decline of an epidemic; (2) the percentage of a population with immunity, whether it exceeds a given threshold or not; and/or (3) the indirect benefit afforded by collective immunity to those who are less immune. Moreover, the accumulation of immune individuals in a population can lead to two different outcomes: elimination (for measles, smallpox, etc) or endemic equilibrium (for COVID-19, influenza, etc). We argue that the strength of a moral obligation for individuals to contribute to herd immunity through vaccination, and by extension the acceptability of coercion, will depend on how 'herd immunity' is interpreted as well as facts about a given disease or vaccine. Among other things, not all uses of 'herd immunity' are equally valid for all pathogens. The optimal conditions for herd immunity threshold effects, as illustrated by measles, notably do not apply to the many pathogens for which reinfections are ubiquitous (due to waning immunity and/or antigenic variation). For such pathogens, including SARS-CoV-2, mass vaccination can only be expected to delay rather than prevent new infections, in which case the obligation to contribute to herd immunity is much weaker, and coercive policies less justifiable.

Citing Articles

[Rapid vaccination monitoring and its impact on vaccination coverage for high-quality catch-up campaigns in the Dominican Republic, 2023Monitoramento das estratégias de vacinação e impacto nas coberturas de vacinação para campanhas de seguimento de...].

Vargas A, Mateo A, Bello Z, Rodriguez Y, Lemos D, Duron Andino R Rev Panam Salud Publica. 2024; 48:e125.

PMID: 39687246 PMC: 11648034. DOI: 10.26633/RPSP.2024.125.


Exploring pathogen population density as a metric for understanding post-COVID infectious disease surges.

Zhang L Front Immunol. 2024; 15:1459628.

PMID: 39421748 PMC: 11484442. DOI: 10.3389/fimmu.2024.1459628.


Immunogenicity and Safety of SARS-CoV-2 Protein Subunit Recombinant Vaccine (IndoVac) as a Heterologous Booster Dose against COVID-19 in Indonesian Adolescents.

Fadlyana E, Rusmil K, Dwi Putra M, Fulendry F, Somantri N, Putri A Vaccines (Basel). 2024; 12(8).

PMID: 39204062 PMC: 11360245. DOI: 10.3390/vaccines12080938.

References
1.
Morens D, Folkers G, Fauci A . The Concept of Classical Herd Immunity May Not Apply to COVID-19. J Infect Dis. 2022; 226(2):195-198. PMC: 9129114. DOI: 10.1093/infdis/jiac109. View

2.
Delamater P, Street E, Leslie T, Yang Y, Jacobsen K . Complexity of the Basic Reproduction Number (R). Emerg Infect Dis. 2018; 25(1):1-4. PMC: 6302597. DOI: 10.3201/eid2501.171901. View

3.
Ridenhour B, Kowalik J, Shay D . Unraveling R0: considerations for public health applications. Am J Public Health. 2013; 104(2):e32-41. PMC: 3935673. DOI: 10.2105/AJPH.2013.301704. View

4.
Eguia R, Crawford K, Stevens-Ayers T, Kelnhofer-Millevolte L, Greninger A, Englund J . A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021; 17(4):e1009453. PMC: 8031418. DOI: 10.1371/journal.ppat.1009453. View

5.
Rota J, Hickman C, Sowers S, Rota P, Mercader S, Bellini W . Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J Infect Dis. 2011; 204 Suppl 1:S559-63. DOI: 10.1093/infdis/jir098. View